MedTrace Logo

Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole

NCT00038038 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2012-08-01

No results posted yet for this study

Summary

The purpose of this clinical research study is to answer the following questions using 18F-fluoromisonidazole as an imaging agent:

1. Do cells exist in human tumors that are at very low oxygen levels (hypoxic cells)?
2. If hypoxic cells exist in human tumors, do they effect the ability of radiotherapy to control human tumors?
3. Can Positron Emission Tomography (PET scanning) detect hypoxic cells in human tumors?

Conditions

Interventions

DRUG

18F-fluoromisonidazole

Small amount of radioactive traces drug given by intravenous injection prior to PET Scan

PROCEDURE

PET scan

Series of pictures using 20 minute scan performed 2 hours after an 18F-fluoromisonidazole injection

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Donald A Podoloff, M.D. · UT MD Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-01-31
Primary Completion
2003-06-30
Completion
2003-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00038038 on ClinicalTrials.gov